v3.24.3
Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Research and development expenses        
Expenses incurred $ 257 $ 469 $ 881 $ 1,570
Less- government grants (52) (387)
Research and development expenses, net 205 469 494 1,570
Marketing expenses 29 297 225 631
General and administrative expenses 367 431 898 1,448
Total operating loss 601 1,197 1,617 3,649
Financial expenses (income), net (3) (18) 4 (11)
Loss for the period $ 598 $ 1,179 $ 1,621 $ 3,638
Basic loss per common stock $ (0.01) $ (0.02) $ (0.02) $ (0.05)
Dilutive loss per common stock $ (0.01) $ (0.02) $ (0.02) $ (0.05)
Weighted average number of ordinary shares - basic 70,758,796 68,836,598 70,305,346 69,233,573
Weighted average number of ordinary shares - diluted 70,758,796 68,836,598 70,305,346 69,233,573

Source